Physician profile
Celeste Latto
NPI 1669613428
$1,865.24
in general payments reported to CMS, 2019-2025
25 companies · $641 in 2025
The $641 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.16 · 2022: $132 · 2023: $557 · 2024: $498 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.94 | 2023-2025 | |
| Pfizer INC. | $187.50 | 2023-2025 | |
| Novo Nordisk INC | $181.31 | 2023-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $152.98 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $116.44 | 2022 | |
| Amgen INC. | $115.22 | 2025 | |
| Lilly USA, LLC | $105.19 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $93.87 | 2023-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $87.43 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.95 | 2023-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $66.85 | 2023 | |
| Boston Scientific Corporation | $47.40 | 2023-2025 | General - Pain Management, Watchman Access System |
| Opko Pharmaceuticals, LLC | $40.50 | 2023 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.47 | 2023 | Jardiance |
| Astellas Pharma US INC | $29.29 | 2024 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $25.01 | 2025 | Sunosi |
| Dexcom, INC. | $22.05 | 2021 | |
| Corcept Therapeutics | $21.51 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $17.19 | 2023 | |
| Tms Neurohealth Centers INC. | $16.03 | 2025 | Tms Neurohealth Centers INC. |
| Phadia US INC. | $15.71 | 2022 | |
| Amarin Pharma, INC. | $15.11 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.04 | 2023 | Quviviq |
| Antares Pharma, INC. | $14.82 | 2025 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $14.43 | 2023 | Livalo, Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Latto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.